Seldom mentioned in scientific literature, aeruginascin is closely structurally related to psilocybin, the most well-known psychoactive compound in magic mushrooms.
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.
There are many compounds closely resembling psilocybin from a chemical structure standpoint. However, the chemical and pharmacological understanding of these psilocybin derivatives is few and far between.
Psilocybin gets most of the attention, and other psilocybin-like compounds present in magic mushrooms have been largely ignored.
Recent studies on the biosynthesis of psilocybin provide an answer to this age-old question.
Researchers measured the effects of psilocybin in depressed people by comparing brain scan data.